Skip to content
PatentBrief
Get alertsTop ↑

Tiny Fat Bubbles That Deliver Drugs Directly to the Liver

This patent describes special tiny fat bubbles, called lipid nanoparticles, designed to carry gene therapy drugs efficiently and specifically to liver cells for treating liver diseases.

Granted 2022ActiveExpires 2041Owned by EnhancedbioInvented by Hyokyoung KWON, Michaela JEONG, Hyukjin Lee + 3 more

Original patent title: “Lipid nanoparticles for in-vivo drug delivery, and uses thereof”

Plain-English explanation by SahiLast reviewed · November 5, 2026

This patent describes special tiny fat bubbles, called lipid nanoparticles, designed to carry gene therapy drugs efficiently and specifically to liver cells for treating liver diseases. Granted to Enhancedbio in 2022 with 18 claims, and it is expected to expire in 2041.

Coverage

What does this patent actually cover?

This patent claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → a specific type of lipid nanoparticle (LNP) designed for delivering drugs inside the body. The LNP is made from a precise mix of four main ingredients: an 'ionizable lipid' (which changes its charge depending on acidity), a 'phospholipid', 'cholesterol', and a 'lipid-PEG conjugate' (claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1). These tiny particles are engineered to specifically target liver tissue, including liver cells (hepatocytes) and liver blood vessel lining cells (LSECs) (claims 7, 8, 9). They can encapsulate and deliver 'anionic drugs' or 'nucleic acids' like mRNA or siRNA (claim 10, 14), which are important for gene therapy. For example, these LNPs could carry an siRNA to the liver to silence a gene causing a specific liver disease.

The gap

What does this patent NOT cover?

  • Does not cover lipid nanoparticles that lack any of the four specific components: an ionizable lipid, a phospholipid, cholesterol, or a lipid-PEG conjugate (claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
  • Does not cover lipid nanoparticles where the lipid-PEG conjugate is outside the range of 0.5 to 5 mol % (claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
  • Does not cover drug delivery methods using non-anionic drugs or drugs that are not nucleic acids (claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 10).
  • Does not cover lipid nanoparticles that do not specifically target liver tissue or liver cells (claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → 7, 8, 9).
  • Does not cover lipid nanoparticles with an average diameter outside the range of 30 nm to 150 nm (claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 12).

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 11464870
StatusActive
FieldBiotech & Medicine
AssigneeEnhancedbio
InventorsHyokyoung KWON, Michaela JEONG, Hyukjin Lee and 3 others
Filed2021
Granted2022
Expires2041
Claims18
Times cited0
LitigationNone on record
Value · $70K–$225KModest

What made this novel

The clever part is the precise combination and ratios of the lipid components, especially the ionizable lipid and the small amount of lipid-PEG conjugate, which allows the nanoparticle to specifically target liver cells while efficiently encapsulating and releasing nucleic acid drugs. The specific pKa range of 6.0 to 7.0 (claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 6) is key, allowing the nanoparticle to be stable in the bloodstream but release its cargo once inside the slightly more acidic environment of a cell's endosome.

The Patent Drawing

Representative patent drawing for Lipid nanoparticles for in-vivo drug delivery, and uses thereof (US 11464870)
Representative figure · US 11464870All figures on Google Patents →
Lipid nanoparticles for in-viv…(Primary claim)biotechpharmaceuticalgene editingtelecommunications

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

mRNA vaccines (like Pfizer-BioNTech and Moderna COVID-19 vaccines, which use LNPs for delivery)

02

Gene therapies for liver diseases (e.g., Alnylam's Onpattro for ATTR amyloidosis)

03

Experimental treatments for hepatitis B virus

04

Drug delivery systems for genetic disorders affecting the liver

Why it matters

The bigger picture

Targeting drugs directly to specific organs like the liver is a major challenge in medicine, especially for gene therapies. This patent offers a way to create lipid nanoparticles that are highly efficient and biocompatible, meaning they are less likely to cause harm. By specifically delivering nucleic acids to the liver, these nanoparticles could help treat serious liver conditions like ATTR amyloidosis, hypercholesterolemia, and hepatitis B virus infection (claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 16).

Filed

October 19, 2021

Granted

October 11, 2022

Market context

Who's building on this

Companies in this space

Companies like Moderna, BioNTech, and Alnylam are major players in the lipid nanoparticle drug delivery space, particularly for mRNA vaccines and gene therapies. Alnylam Pharmaceuticals, for instance, has developed an LNP-based siRNA therapy for a liver-related genetic condition. Enhancedbio, the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is actively developing this technology.

Market impact

Lipid nanoparticles have revolutionized drug delivery, particularly in the field of gene therapy and vaccine development. This patent contributes to the ongoing effort to create more targeted and efficient delivery systems, which could lead to new treatments for a range of diseases, especially those affecting the liver. The success of mRNA vaccines during the COVID-19 pandemic highlighted the immense potential and commercial viability of LNP technology, driving further investment and research in this area.

Claim 1 — Plain English

What this patent covers

This patent claims a specific type of lipid nanoparticle (LNP) designed for delivering drugs inside the body. The LNP is made from a precise mix of four main ingredients: an 'ionizable lipid' (which changes its charge depending on acidity), a 'phospholipid', 'cholesterol', and a 'lipid-PEG conjugate' (claim 1). These tiny particles are engineered to specifically target liver tissue, including liver cells (hepatocytes) and liver blood vessel lining cells (LSECs) (claims 7, 8, 9). They can encapsulate and deliver 'anionic drugs' or 'nucleic acids' like mRNA or siRNA (claim 10, 14), which are important for gene therapy. For example, these LNPs could carry an siRNA to the liver to silence a gene causing a specific liver disease.

The clever bit

The clever part is the precise combination and ratios of the lipid components, especially the ionizable lipid and the small amount of lipid-PEG conjugate, which allows the nanoparticle to specifically target liver cells while efficiently encapsulating and releasing nucleic acid drugs. The specific pKa range of 6.0 to 7.0 (claim 6) is key, allowing the nanoparticle to be stable in the bloodstream but release its cargo once inside the slightly more acidic environment of a cell's endosome.

What it does not cover

  • Does not cover lipid nanoparticles that lack any of the four specific components: an ionizable lipid, a phospholipid, cholesterol, or a lipid-PEG conjugate (claim 1).
  • Does not cover lipid nanoparticles where the lipid-PEG conjugate is outside the range of 0.5 to 5 mol % (claim 1).
  • Does not cover drug delivery methods using non-anionic drugs or drugs that are not nucleic acids (claim 10).
  • Does not cover lipid nanoparticles that do not specifically target liver tissue or liver cells (claims 7, 8, 9).
  • Does not cover lipid nanoparticles with an average diameter outside the range of 30 nm to 150 nm (claim 12).

Patent timeline

Filing

Application submitted to the patent office

Publication

Application published, typically 18 months after filing

Grant

Patent officially issued

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Early stage

Citation count

0/40

No citations yet

Claim breadth

12/20

Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →

Recency

20/20

Granted within 5 years

Assignee scale

0/20

Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Modest

$70K – $225K

Midpoint $140K · 14.9 yr remaining · industry ×3.0

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

18 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Citations

Patent lineage

Cites earlier patents

7

earlier patents this invention cites as foundations

View prior art →

Cite this patent

KWON, H., JEONG, M., Lee, H., Kim, M., JEONG, H., & SEO, Y. (2022). Tiny Fat Bubbles That Deliver Drugs Directly to the Liver (U.S. Patent No. 11,464,870). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/11464870/lipid-nanoparticles-for-in-vivo-drug-delivery-and-uses-thereof

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US11464870"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:biotech patents →pharmaceutical patents →gene editing patents →

Common Questions

Frequently Asked Questions

What does Tiny Fat Bubbles That Deliver Drugs Directly to the Liver cover?

This patent describes special tiny fat bubbles, called lipid nanoparticles, designed to carry gene therapy drugs efficiently and specifically to liver cells for treating liver diseases.

Who owns patent US 11464870?

Enhancedbio owns this patent, granted in 2022.

When does this patent expire?

This patent is expected to expire on October 19, 2041, when the invention enters the public domain.

What problem does this patent solve?

Targeting drugs directly to specific organs like the liver is a major challenge in medicine, especially for gene therapies. This patent offers a way to create lipid nanoparticles that are highly efficient and biocompatible, meaning they are less likely to cause harm. By specifically delivering nucleic acids to the liver, these nanoparticles could help treat serious liver conditions like ATTR amyloidosis, hypercholesterolemia, and hepatitis B virus infection (claim 16).

What does this patent NOT cover?

Does not cover lipid nanoparticles that lack any of the four specific components: an ionizable lipid, a phospholipid, cholesterol, or a lipid-PEG conjugate (claim 1).

Patent monitoring

Get notified when Enhancedbio files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: November 5, 2026 · PatentBrief is not a law firm and this is not legal advice.